Lexaria Bioscience Corp. LXRP Archives - Page 15 of 27

MondayOct 22, 2018 10:56 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Has Filed New Patent Application in Strategic Effort to Build Global Portfolio

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), in a strategic effort to build its global intellectual property (IP) portfolio, has filed a new patent application for its proprietary absorption technology platform. An article discussing this reads, “It has filed a provisional application in a tenth patent family relating to the applicability of DehydraTECH’s imparting benefits to tobacco leaves to deliver compounds that may or may not include nicotine. That patent family is ‘Lipophilic Active Agent Infused Tobacco Leaves and/or Tobacco Materials and Methods of Use Thereof.’” To view the full article, visit http://ibn.fm/zsdzq About Lexaria Bioscience Corp. Lexaria Bioscience Corp. licenses…

FridayOct 19, 2018 10:40 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Focused on Innovative Nicotine Delivery to Provide Healthier Alternatives to Lighting Up

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is on a quest in the development of healthier nicotine ingestion methods to provide consumers alternatives to lighting up. A recent article discussing the company’s novel drug delivery platform reads, “In a press release from August 2018, Lexaria announced a second-generation study in 40 rats. The study resulted in Lexaria’s formulation being four-times faster at reaching its peak level in brain tissue than the non-enhanced control formulation. In a press release (http://ibn.fm/d7ur9), Chris Bunka, chief executive officer of Lexaria, stated, ‘DehydraTECH delivery technology continues to demonstrate its superior effectiveness in delivering nicotine without the…

ThursdayOct 18, 2018 9:02 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Granted Two New US Patents

Drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) this morning announced that it has been granted two new U.S. patents. Per the update, the two new patents are related to certain cannabinoid infused beverage compositions utilizing Lexaria’s proprietary DehydraTECH process, a process which continues to strengthen the company’s dominant intellectual property position in the growing cannabis beverage market. With these new additions, Lexaria now has six granted patents in the U.S. and four granted patents in Australia, all 10 of which fall within the company’s first patent family, “Food and Beverage Compositions Infused With Lipophilic Active Agents…

TuesdayOct 16, 2018 11:27 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Completes Establishment of Four Wholly Owned Subsidiaries

Lexaria’s technology changes the manner in which edible cannabinoids enter the body The company out-licenses its DehydraTECH drug delivery platform Lexaria recently announced the creation of four wholly owned subsidiaries A research-driven company, Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is the only company globally that has been awarded a patent for the improved delivery of all cannabinoids. It has developed and out-licenses its DehydraTECH technology – a drug delivery platform. This technology is a complementary layer that works with other research and development being conducted on cannabinoids and, as such, is an enabling technology, not a competing one. Lexaria…

WednesdayOct 10, 2018 12:45 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Infuses Cannabis Industry, Delivers Results with Innovative Drug Delivery Platform

Global legal cannabis market projected to surpass $146 billion by end of 2025 Cannabinoid-infused edibles, concentrates represent fastest-growing segment of industry Lexaria’s patented technology improves bio-absorption and bioavailability of active ingredients while masking unpleasant taste Lucrative licensing business model includes agreements to enhance cannabinoid (CBD) delivery before year-end 2018 Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and its proprietary technology found in the company’s drug delivery platform DehydraTECH has application for several subsets of the cannabis industry and other pharmacological verticals. As a technology proven to deliver increased intestinal absorption rates and higher bioavailability for a number of bioactive compounds,…

WednesdayOct 10, 2018 9:26 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Unveils Four New Subsidiary Companies

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced the creation of four new wholly-owned subsidiary companies: Lexaria CanPharm Corp., a Canadian company that provides DehydraTECH technology and other enhancements to the global cannabis industry; Lexaria Nicotine Corp., a US company with a global license to offer DehydraTECH technology to the global nicotine and tobacco industries; Lexaria Hemp Corp., a US company globally licensed to provide DehydraTECH to the burgeoning hemp-based foods and supplements industries; and Lexaria Pharmaceutical Corp., a US company internationally authorized to license DehydraTECH to the pharmaceutical sector, including pain relief, vitamins, hormone treatments, central nervous system…

MondayOct 08, 2018 1:50 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Strengthens IP Portfolio

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is building its strategic intellectual property (“IP”) portfolio with two recent Notices of Allowance from the U.S. Patent and Trademark Office (“USPTO”) as well as the addition of three new patents in Australia. The company anticipates receiving additional patents in the U.S. by the end of the year. An article discussing Lexaria reads, “If all are issued, LXRP will then hold 12 issued patents within its first patent family, “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof.” It would strengthen LXRP’s IP claims in both countries. All new…

WednesdayOct 03, 2018 3:23 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Extends List of Applicable Uses for Innovative Drug Delivery Platform

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) continues to leverage its drug delivery platform technology in exciting new markets. An article discussing the company reads, “It has patents granted in the U.S. and Australia for applications of its DehydraTECH™ technology. Moreover, the company has many patents pending in over 40 nations. Lexaria Bioscience’s business strategy involves expanding the applicability of its technology within and beyond the cannabinoid sector. Recently upgraded to the OTC Markets’ OTCQX Best Market, Lexaria Bioscience is based in Kelowna, British Columbia. … The DehydraTECH™ drug delivery platform promotes healthier ingestion methods. It considerably improves the body’s ability…

MondayOct 01, 2018 1:03 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Changing the Efficiency and Future of Drug Delivery

Focused on discovering new technologies that deliver cannabinoids and other beneficial molecules to the bloodstream Bypassing the negative side effects of lighting up Crossing blood brain barrier Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is focused on discovering new technologies that deliver cannabinoids and other lipophilic (fat soluble) beneficial molecules to the bloodstream through efficient and healthy ingestion. The first step to discovering how to deliver a higher percentage into the human bloodstream was to find a way to protect the molecules on their journey through the gastrointestinal system. It was discovered that fats are an excellent conduit, increasing absorption…

FridaySep 28, 2018 9:55 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Announces Filing of New Strategic Patent Application

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a drug delivery platform innovator, this morning announced the filing of a new strategic patent application. Per the update, the new provisional patent application is entitled "Lipophilic Active Agent Infused Tobacco Leaves and/or Tobacco Materials and Methods of Use Thereof" and represents Lexaria’s tenth patent family, expanding the applicability of the already-patented DehydraTECH technological process to impart benefits to tobacco leaves that may be utilized to deliver compounds that may or may not include nicotine. Notably, Lexaria intends to manage between 150 and 200 patent applications around the world within two years. To…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LXRP